Biography
Lord Sharkey has engaged on health and social care through two debate speeches covering distinct topics. He raised concerns about the early access programme for rare disease treatments, specifically questioning the effectiveness of the givinostat approval process for Duchenne Muscular Dystrophy and what happens to patients if NICE declines the drug. He also contributed to debate on National Insurance Contributions legislation, criticising the Bill for exacerbating existing problems and failing to adequately address social care funding.
Generated from their own Hansard record, below
“My Lords, I declare an interest as a trustee of Muscular Dystrophy UK. Following the previous question, can the Minister say whether the early access programme really works? How many other drugs have been licensed under the programme, how many were eventually approved by NICE and how many were declined? If the applicat…”
Record by topic
- GP access205th of 2412.0
- Rare diseases170th of 2022.0
What they’ve said
“…What about the additional payroll cost to GP practices? The Institute of General Practice Management estimates that the NI rise will mean that the average GP surgery tax bill will rise by around £20,000 a year.”
National Insurance Contributions (Secondary Class 1 Contributions) Bill · 2025-01-06 · Read on Hansard ↗
Contributions reproduced under the Open Parliament Licence.
Related media coverage
Recent UK press coverage of their topics — not necessarily quoting them directly.